{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:55:45Z","timestamp":1789646145358,"version":"4.0.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01HL127518-01"],"award-info":[{"award-number":["1U01HL127518-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA216722"],"award-info":[{"award-number":["R21CA216722"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jbc.2025.110809","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:04:01Z","timestamp":1759939441000},"page":"110809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis"],"prefix":"10.1016","volume":"301","author":[{"given":"Howard","family":"Donninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Ferrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becca","family":"von Baby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3978-416X","authenticated-orcid":false,"given":"Katie R.","family":"Hobbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-738X","authenticated-orcid":false,"given":"Nagaraju","family":"Miriyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-7132","authenticated-orcid":false,"given":"Raphael","family":"Jigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2592-4991","authenticated-orcid":false,"given":"Joseph","family":"Burlison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Monsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6750-5682","authenticated-orcid":false,"given":"Geoffrey J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110809_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110809_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fonc.2019.00965","article-title":"RAS: striking at the core of the oncogenic circuitry","volume":"9","author":"Gimple","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2025.110809_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcdb.2016.07.012","article-title":"The role of wild type RAS isoforms in cancer","volume":"58","author":"Zhou","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/fmc.11.121","article-title":"Inhibition of Ras for cancer treatment: the search continues","volume":"3","author":"Baines","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jbc.2025.110809_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/gad.352081.124","article-title":"\"Undruggable KRAS\": druggable after all","author":"Cox","year":"2024","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.110809_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0962-8924(00)01740-2","article-title":"Understanding ras: 'it ain't over 'til it's over'","volume":"10","author":"Shields","year":"2000","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-090514-030732","article-title":"B-Raf inhibition in the Clinic: present and future","volume":"67","author":"Fiskus","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jbc.2025.110809_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2025.110809_bib10","first-page":"1","article-title":"Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and Non-Hodgkin lymphoma","author":"Kienle","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jbc.2025.110809_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc2296","article-title":"RAL GTPases and cancer: linchpin support of the tumorigenic platform","volume":"8","author":"Bodemann","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2025.110809_bib12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1101\/gad.993902","article-title":"Distinct requirements for Ras oncogenesis in human versus mouse cells","volume":"16","author":"Hamad","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.110809_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccr.2005.04.030","article-title":"Activation of RALA is critical for Ras-induced tumorigenesis of human cells","volume":"7","author":"Lim","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-19-1255","article-title":"Can the help match the hype? KRAS(G12C)-Specific inhibitors and beyond","volume":"10","author":"Klempner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbc.2025.110809_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/0929867330666230330122000","article-title":"First approval of adagrasib for the treatment of non-small cell lung cancer harboring a KRAS(G12C) mutation","volume":"31","author":"De","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110809_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110809_bib17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-Driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbc.2025.110809_bib18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110809_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110809_bib20","doi-asserted-by":"crossref","first-page":"34729","DOI":"10.1074\/jbc.M110.116756","article-title":"Aberrant overexpression of the Rgl2 RAL small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through RAL-dependent and RAL-independent mechanisms","volume":"285","author":"Vigil","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110809_bib21","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.cub.2006.10.023","article-title":"Divergent roles for RALA and RALB in malignant growth of human pancreatic carcinoma cells","volume":"16","author":"Lim","year":"2006","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib22","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1128\/MCB.21.17.5958-5969.2001","article-title":"Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and RAL-specific guanine exchange factor pathways","volume":"21","author":"Ward","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ccr.2005.01.029","article-title":"RALGDS is required for tumor formation in a model of skin carcinogenesis","volume":"7","author":"Gonzalez-Garcia","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib24","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.cub.2012.09.013","article-title":"Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis","volume":"22","author":"Peschard","year":"2012","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib25","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cellsig.2010.05.010","article-title":"RALGDS family members couple Ras to RAL signalling and that's not all","volume":"22","author":"Ferro","year":"2010","journal-title":"Cell Signal."},{"key":"10.1016\/j.jbc.2025.110809_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.08.034","article-title":"RALB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival","volume":"127","author":"Chien","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000423369","article-title":"Tumor microenvironment: paracrine and autocrine growth mechanisms and metastasis to specific sites","volume":"28","author":"Nicolson","year":"1994","journal-title":"Front. Radiat. Ther. Oncol."},{"key":"10.1016\/j.jbc.2025.110809_bib28","first-page":"89","article-title":"Brain metastasis: role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the centRAL nervous system","volume":"213","author":"Nicolson","year":"1996","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"10.1016\/j.jbc.2025.110809_bib29","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-11-3966","article-title":"Transcriptional signatures of RAL GTPase are associated with aggressive clinicopathologic characteristics in human cancer","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110809_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ncb2953","article-title":"An integrin beta(3)-KRAS-RALB complex drives tumour stemness and resistance to EGFR inhibition","volume":"16","author":"Seguin","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/sj.embor.embor899","article-title":"RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival","volume":"4","author":"Chien","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jbc.2025.110809_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ccr.2005.10.014","article-title":"Reduction in the requirement of oncogenic Ras signaling to activation of PI3K\/AKT pathway during tumor maintenance","volume":"8","author":"Lim","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nsb0897-609","article-title":"Three-dimensional structure of the ras-interacting domain of RALGDS","volume":"4","author":"Huang","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.jbc.2025.110809_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2025.110809_bib35","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","article-title":"Patient-derived tumor xenografts: transforming clinical samples into mouse models","volume":"73","author":"Siolas","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110809_bib36","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jbc.2025.110809_bib37","article-title":"Overcoming adaptive resistance to KRAS and MEK inhibitors by Co-targeting mTORC1\/2 complexes in pancreatic cancer","volume":"1","author":"Brown","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jbc.2025.110809_bib38","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission Possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2025.110809_bib39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/1471-2407-12-612","article-title":"Alternative dosing of dual PI3K and MEK inhibition in cancer therapy","volume":"12","author":"Jokinen","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbc.2025.110809_bib40","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/onc.2009.521","article-title":"Dissection of RAS downstream pathways in melanomagenesis: a role for RAL in transformation","volume":"29","author":"Mishra","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2025.110809_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100750","article-title":"Covalent fragment screening identifies Rgl2 RALGEF cysteine for targeted covalent inhibition of RAL GTPase activation","volume":"17","author":"Bum-Erdene","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jbc.2025.110809_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/jsre.1998.5417","article-title":"ORAL dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice","volume":"79","author":"Muscarella","year":"1998","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.jbc.2025.110809_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.117.014415","article-title":"RAL GTPases: biology and potential as therapeutic targets in cancer","volume":"70","author":"Yan","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jbc.2025.110809_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1947601911407329","article-title":"The RALGEF-RAL effector signaling network: the road less traveled for anti-ras drug discovery","volume":"2","author":"Neel","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jbc.2025.110809_bib45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110809_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jbc.2025.110809_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0076-6879(95)55042-9","article-title":"Biological assays for Ras transformation","volume":"255","author":"Clark","year":"1995","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jbc.2025.110809_bib48","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.C000463200","article-title":"Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis","volume":"275","author":"Vos","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110809_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ddtec.2004.11.012","article-title":"Analytical ultracentrifugation: a powerful 'new' technology in drug discovery","volume":"1","author":"Laue","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jbc.2025.110809_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-59745-367-7_4","article-title":"Protein-protein and ligand-protein interactions studied by analytical ultracentrifugation","volume":"490","author":"Stafford","year":"2009","journal-title":"Methods Mol. Biol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825026614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825026614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T12:30:26Z","timestamp":1767270626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825026614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0021925825026614"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110809","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110809"}}